Elena Hesina Yanushpolsky, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Progesterone | 9 | 2023 | 776 | 2.540 |
Why?
|
| Fertilization in Vitro | 15 | 2023 | 1284 | 2.110 |
Why?
|
| Embryo Transfer | 10 | 2021 | 510 | 1.880 |
Why?
|
| Pregnancy Rate | 10 | 2023 | 643 | 1.290 |
Why?
|
| Live Birth | 3 | 2023 | 512 | 1.130 |
Why?
|
| Luteal Phase | 4 | 2015 | 147 | 0.980 |
Why?
|
| Embryo Implantation | 4 | 2021 | 272 | 0.810 |
Why?
|
| Embryo Culture Techniques | 1 | 2021 | 80 | 0.750 |
Why?
|
| Preimplantation Diagnosis | 1 | 2021 | 151 | 0.660 |
Why?
|
| Endometrium | 3 | 2016 | 424 | 0.580 |
Why?
|
| Fertility Agents, Female | 1 | 2015 | 99 | 0.500 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 1813 | 0.480 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2014 | 53 | 0.470 |
Why?
|
| Cryopreservation | 2 | 2016 | 670 | 0.390 |
Why?
|
| Injections, Intramuscular | 5 | 2014 | 552 | 0.390 |
Why?
|
| Premature Birth | 1 | 2023 | 1721 | 0.380 |
Why?
|
| Fertility | 1 | 2015 | 781 | 0.360 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2014 | 370 | 0.360 |
Why?
|
| Semen | 3 | 1996 | 316 | 0.330 |
Why?
|
| Uterine Hemorrhage | 1 | 2010 | 255 | 0.320 |
Why?
|
| Infertility | 1 | 2015 | 655 | 0.310 |
Why?
|
| Infertility, Male | 3 | 1996 | 409 | 0.310 |
Why?
|
| Pregnancy | 15 | 2023 | 29144 | 0.290 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2010 | 63 | 0.260 |
Why?
|
| Estradiol | 3 | 2010 | 2020 | 0.250 |
Why?
|
| Clomiphene | 1 | 2003 | 72 | 0.230 |
Why?
|
| Leukocytes | 3 | 1996 | 2043 | 0.220 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 129 | 0.220 |
Why?
|
| Follicular Phase | 1 | 2023 | 153 | 0.210 |
Why?
|
| Chorionic Gonadotropin | 2 | 2015 | 477 | 0.210 |
Why?
|
| Birth Rate | 1 | 2023 | 170 | 0.200 |
Why?
|
| Insemination, Artificial | 2 | 2000 | 98 | 0.200 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2003 | 744 | 0.190 |
Why?
|
| Ploidies | 1 | 2021 | 281 | 0.190 |
Why?
|
| Blastocyst | 1 | 2021 | 424 | 0.150 |
Why?
|
| Aneuploidy | 1 | 2021 | 530 | 0.150 |
Why?
|
| Abortion, Spontaneous | 2 | 2021 | 544 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2014 | 12720 | 0.140 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 1995 | 15 | 0.130 |
Why?
|
| Suppositories | 1 | 2014 | 15 | 0.130 |
Why?
|
| Catheterization | 1 | 2000 | 1470 | 0.120 |
Why?
|
| Pregnancy Outcome | 3 | 2021 | 2795 | 0.120 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1995 | 233 | 0.120 |
Why?
|
| Oocytes | 1 | 1998 | 1187 | 0.110 |
Why?
|
| Oocyte Retrieval | 1 | 2014 | 161 | 0.110 |
Why?
|
| Spermatozoa | 1 | 1996 | 625 | 0.110 |
Why?
|
| Trophoblasts | 1 | 1993 | 215 | 0.100 |
Why?
|
| Female | 20 | 2023 | 380194 | 0.100 |
Why?
|
| Embryo, Mammalian | 1 | 1998 | 1701 | 0.100 |
Why?
|
| Progesterone Congeners | 1 | 2010 | 42 | 0.090 |
Why?
|
| Germ Cells | 1 | 1994 | 631 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 3396 | 0.090 |
Why?
|
| Endometriosis | 1 | 1998 | 839 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 1205 | 0.080 |
Why?
|
| Benchmarking | 1 | 2015 | 1042 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2021 | 3444 | 0.080 |
Why?
|
| Estrogens | 1 | 2015 | 1566 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2014 | 787 | 0.080 |
Why?
|
| Adult | 13 | 2021 | 214055 | 0.080 |
Why?
|
| Humans | 22 | 2023 | 744343 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2015 | 63114 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2014 | 3913 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4933 | 0.070 |
Why?
|
| Sperm Count | 2 | 1998 | 216 | 0.070 |
Why?
|
| Ovarian Cysts | 2 | 1998 | 115 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6489 | 0.060 |
Why?
|
| Maternal Age | 1 | 2007 | 802 | 0.060 |
Why?
|
| Granulocytes | 2 | 1996 | 548 | 0.060 |
Why?
|
| Linear Models | 1 | 2014 | 5952 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77449 | 0.060 |
Why?
|
| Age Factors | 3 | 2007 | 18370 | 0.060 |
Why?
|
| Administration, Intravaginal | 1 | 2001 | 150 | 0.050 |
Why?
|
| Gamete Intrafallopian Transfer | 1 | 2001 | 27 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 54 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 1996 | 1588 | 0.050 |
Why?
|
| Isoflavones | 1 | 2001 | 139 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2007 | 2373 | 0.050 |
Why?
|
| Gels | 1 | 2001 | 427 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2003 | 551 | 0.040 |
Why?
|
| Ovulation Induction | 1 | 2001 | 274 | 0.040 |
Why?
|
| Hysteroscopy | 1 | 2000 | 102 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.040 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2001 | 271 | 0.040 |
Why?
|
| Cytokines | 1 | 1993 | 7322 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 40075 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 4838 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 1995 | 7181 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2000 | 1107 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 2000 | 590 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2886 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 1998 | 286 | 0.030 |
Why?
|
| Sperm Motility | 1 | 1996 | 253 | 0.030 |
Why?
|
| Sulfamethoxazole | 1 | 1995 | 53 | 0.030 |
Why?
|
| Trimethoprim | 1 | 1995 | 91 | 0.030 |
Why?
|
| Doxycycline | 1 | 1995 | 326 | 0.030 |
Why?
|
| Demography | 1 | 1998 | 1656 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2000 | 53288 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1353 | 0.030 |
Why?
|
| Incidence | 1 | 2010 | 20947 | 0.030 |
Why?
|
| Obesity | 1 | 2014 | 12745 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 40561 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1995 | 604 | 0.020 |
Why?
|
| Survivors | 1 | 2001 | 2291 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1263 | 0.020 |
Why?
|
| Vagina | 1 | 1995 | 825 | 0.020 |
Why?
|
| Abscess | 1 | 1993 | 607 | 0.020 |
Why?
|
| Male | 6 | 2015 | 350118 | 0.020 |
Why?
|
| Pelvis | 1 | 1993 | 730 | 0.020 |
Why?
|
| Logistic Models | 1 | 2003 | 13408 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 56430 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15076 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1993 | 2126 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1993 | 3206 | 0.020 |
Why?
|
| Testosterone | 1 | 1995 | 2420 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1998 | 2861 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 168757 | 0.010 |
Why?
|
| Cell Survival | 1 | 1993 | 5882 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1993 | 4420 | 0.010 |
Why?
|
| Phytoestrogens | 1 | 2001 | 61 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 2001 | 167 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2001 | 94 | 0.010 |
Why?
|
| Self Administration | 1 | 2001 | 385 | 0.010 |
Why?
|
| Plants | 1 | 2001 | 316 | 0.010 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2001 | 160 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1998 | 21746 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 12959 | 0.010 |
Why?
|
| Cell Line | 1 | 1993 | 15997 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1995 | 5256 | 0.010 |
Why?
|
| Medical Records | 1 | 2001 | 1413 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2001 | 906 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1995 | 39050 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1993 | 354 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6365 | 0.010 |
Why?
|
| Neoplasms | 1 | 2001 | 21683 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2001 | 3297 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 4215 | 0.010 |
Why?
|
| Middle Aged | 1 | 1995 | 213383 | 0.000 |
Why?
|